论文部分内容阅读
患转移癌的54例病人,在应用高剂量(100～120mg/m~2)顺铂化疗过程中进行听力监测研究。81%的病人在化疗完成后,其气导听阈表现出显著的变化;13%听力失去实用能力。但个体差异很大,有的病人一个疗程后即出现严重听力下降,而另一些病人三个疗程后其听力未受影响。经过对不同剂量、不同给药方式、不同年龄、给药前后听力测定及血浆浓度监测的研究得出:每一疗程高剂量顺铂治疗后,25%的病人丧失原有高频听阈的25%,化疗完成后,41%的病人在中频范围气导听阈显
54 patients with metastatic cancer underwent high-dose (100 ~ 120mg / m ~ 2) Cisplatin chemotherapy during hearing monitoring study. After the completion of chemotherapy, 81% of patients showed significant changes in their air conduction thresholds; 13% of their hearing loss of practical ability. However, individual differences are quite large. Some patients experience severe hearing loss after one course of treatment, while others have no effect on their hearing after three courses of treatment. After different doses, different modes of administration, different ages, before and after the hearing test and plasma concentration monitoring study found that: each course of high-dose cisplatin treatment, 25% of patients lost the original high-frequency hearing threshold of 25% After completion of chemotherapy, 41% of patients in the mid-range air conduction hearing threshold was significantly